Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Acorda Therapeutics, Inc. has announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases.
Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award was presented at the 2010 NORD Partners in Progress Gala in Washington, D.C.
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments.”
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. ”NORD is also an invaluable resource for people affected by rare diseases, providing information, education and support services to patients, families, medical professionals, and the public. We are honored to be recognized by an organization that has made such important contributions to medicine and society.”
“Multiple sclerosis is a progressive disease with devastating health consequences, and new treatment options are needed to improve the lives of people with MS,” said Peter L. Saltonstall, President and CEO of NORD. “We commend Acorda for its commitment to bringing novel therapies to market for people with MS and other neurological diseases.”
In the United States, a disease is considered rare if it affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 such diseases. Although MS is now estimated to affect between 400,000-500,000 Americans, it was classified as a rare disease at the time that Acorda began developing AMPRYA.
Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award was presented at the 2010 NORD Partners in Progress Gala in Washington, D.C.
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments.”
“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. ”NORD is also an invaluable resource for people affected by rare diseases, providing information, education and support services to patients, families, medical professionals, and the public. We are honored to be recognized by an organization that has made such important contributions to medicine and society.”
“Multiple sclerosis is a progressive disease with devastating health consequences, and new treatment options are needed to improve the lives of people with MS,” said Peter L. Saltonstall, President and CEO of NORD. “We commend Acorda for its commitment to bringing novel therapies to market for people with MS and other neurological diseases.”
In the United States, a disease is considered rare if it affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 such diseases. Although MS is now estimated to affect between 400,000-500,000 Americans, it was classified as a rare disease at the time that Acorda began developing AMPRYA.
